Valiant Laboratories

Valiant Laboratories Equity Turnover

The Equity Turnover of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 0.76. In the previous year, Equity Turnover was 0.59 — a change of 28.93% (higher).

Equity Turnover

0.76

YoY

28.93%

Last updated:

Equity Turnover of Valiant Laboratories is 2026 0.76 . Equity Turnover of Valiant Laboratories was 2025 0.59 . It decreases by 28.93% higher compared to the previous year.

The Valiant Laboratories Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2021
2.06 INR
Jan 1, 2022
4.08 INR
Jan 1, 2023
3.32 INR
Jan 1, 2024
0.77 INR
Jan 1, 2025
0.59 INR
Jan 1, 2026
0.76 INR
The Valiant Laboratories Equity Turnover history
YEAREquity TurnoverYoY
0.76+28.93%
0.59-22.92%
0.77-76.87%
3.32-18.55%
4.08+98.15%
2.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Equity Turnover of Valiant Laboratories is 0.76 in 2026.

Equity Turnover of Valiant Laboratories changed from 0.59 to 0.76, representing a 28.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Valiant Laboratories

All Key Metrics — Valiant Laboratories